Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims 
Biren Technology Targets Hong Kong IPO to Raise $300 Million Amid China’s AI Chip Push 
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
Treasury Wine Estates Shares Plunge on Earnings Warning Amid U.S. and China Weakness 
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies 
Blackstone Leads $400 Million Funding Round in Cyera at $9 Billion Valuation 
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track 
OpenAI Explores Massive Funding Round at $750 Billion Valuation 
Shell M&A Chief Exits After BP Takeover Proposal Rejected 
Amazon in Talks to Invest $10 Billion in OpenAI as AI Firm Eyes $1 Trillion IPO Valuation 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
Robinhood Expands Sports Event Contracts With Player Performance Wagers 
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz 
Republicans Raise National Security Concerns Over Intel’s Testing of China-Linked Chipmaking Tools 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
NEW YORK, Dec. 22, 2016 -- Dr. Pamela Stanley, Professor of Cell Biology at Albert Einstein College of Medicine and Horace W. Goldsmith Foundation Chair, has been selected to join the Education Board at the American Health Council. She will be sharing her knowledge and expertise in Glycobiology and Developmental Biology.
|
|||||
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/65655f30-f80b-42f1-acf7-b0053e60e874
Dr. Stanley has been active in biomedical research for the past 39 years. She obtained her PhD in Virology and Biochemistry in 1972 from the University of Melbourne in Australia and did postdoctoral work at the University of Toronto supported by a MRC Fellowship.
Dr. Stanley has been Professor of Cell Biology at Albert Einstein College of Medicine for 27 years and Horace W. Goldsmith Foundation Chair for 9 years. Her day-to-day responsibilities include mentoring post-doctoral fellows and graduate students in investigations of roles for mammalian glycans in development, cancer, and Notch signaling. She also offers a graduate course in Glycobiology.
Albert Einstein College of Medicine is a premier, research-intensive medical school dedicated to innovative biomedical investigation and the development of ethical and compassionate physicians and scientists. Dr. Stanley takes great pride in being able to make a difference in the lives of post-graduate trainees at such a prestigious institution.
Dr. Stanley’s area of expertise is in diseases that stem from defects in the biosynthesis of glycans, often termed congenital disorders of glycosylation (CDG). Each disease is usually inherited and rare, but together the CDGs comprise mutations in more than 100 human genes. She has been supported by grants from the National Institutes of Health since 1980 and has also received grants from the American Cancer Society, the National Science Foundation and the Mizutani Foundation.
Dr. Stanley, whose interest in science began at the age of 14, attributes success throughout her career to having a keen interest in understanding and discussing experimental details, being flexible, working hard, persevering, and sharing information and reagents with others. She is proud of the extensive research produced by the members of her laboratory on isolating and identifying biochemical and genetic bases of Chinese hamster ovary (CHO) cell glycosylation mutants, in using these mutants, as well as developing mutant mice, to understand functions of of glycans in development and Notch signaling. Her current goals include determining roles for complex N-glycans in spermatogenesis, and for O-glycans in Notch signaling. She is on the Editorial Board of Glycobiology, Glycoconjugate Journal, F1000 Research Reports and Scientific Reports. She is a member of AAUWA, NYAS, ASBMB, ASCB, and SFG, and is a past President of the Society for Glycobiology (SFG).
Dr. Stanley’s awards and honors include: Dunlop Prize for First Place in Biochemistry (1966 and 1967); Australian Society for Microbiology Prize for Virology (1968); Commonwealth post-graduate award (1969-1972); Postdoctoral Fellowship from the Medical Research Council of Canada (1972-1975); American Cancer Society Faculty Awards (1978-1981 and 1981-1983); Irma T. Hirschl Faculty Award (1985-1990); election to Leo M. Davidoff Society for Excellence in Teaching (1987); MERIT Award from the National Cancer Institute, NIH (1991); Dorothy Baugh Harmon Lectureship, Oklahoma Med Res Foundation (1997); Mizutani Awards (2001, 2013); International Glycoconjugate Organization Award (2003); Karl Meyer Award, Society for Glycobiology (2003); Horace W. Goldsmith Foundation Chair (2007); LaDonne Shulman award for graduate teaching (2009); Goldstein Lecture, Dept. Biological Chemistry, U. Michigan, Ann Arbor (2010); Peter Gallagher memorial lecture, Griffith University, Australia (2012); Marshall Horwitz Faculty Prize for Research Excellence (2014); and WALS lecture, National Institutes of Health (2015).
Dr. Stanley can converse in French. In her free time, she enjoys playing tennis and piano, swimming, and reading.
For more information, please contact: Elizabeth Moore American Health Council Hauppauge, NY United States Phone: 1-212-390-0214 Email: [email protected]
